Bioceutical company focusing on alternative plant-based cannabinoids and mental health therapeutic research, Institute of Biomedical Research or M2Bio Sciences (OTCMKTS:MRES), announced the launch of its website. The site has been set up for serving healthcare consumers and professionals, including sections such as a health blog called ‘Digestible Facts.’
On Thursday, MRES stock ended flat at $0.0105 with more than 62.50K shares, compared to volume of 146.72K shares. The stock moved within a range of $0.0105 – 0.0105 after opening trade at $0.0103.
M2Bio Sciences Division M2Biome Cardiometabolic Health Launches Website
A key feature of the website includes a diabetes screening tool, which would tell people about the risks of having undiagnosed type 2 diabetes and urge them to take further tests. It is a vital tool for highlighting lifestyle changes required for lowering the risk of non-communicable diseases. The company’s mission is to give education on nutrition and health as well as create awareness of disease risks.
Nicola Royce, Managing Director of M2Biome said that the prevalence of undiagnosed diabetes in South Africa is about 45%. Royce added that many people only know after developing complications, impacting the quality of life. The Managing Director added that since type 2 diabetes is preventable, he is looking at creating risk awareness and working on validating the African Diabetes Risk Score.
Wilna Eksteen, Cardiometabolic Product Developer said that food should be functional, fun, and user-friendly. Eksteen added that no ingredient should be used that makes people unhealthy and hence cooking should be easy and multi-beneficial.